EDAP TMS S.A. ( (EDAP) ) has released its Q3 earnings. Here is a breakdown of the information EDAP TMS S.A. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EDAP TMS S.A. is a global leader in robotic energy-based therapies, specializing in the development and distribution of minimally invasive medical devices using ultrasound technology, primarily for prostate cancer treatment. In its third-quarter earnings report for 2025, EDAP TMS S.A. highlighted significant growth in its High-Intensity Focused Ultrasound (HIFU) business, driven by increased sales of its Focal One system and a rise in U.S. procedure volumes. The company reported a 49% year-over-year increase in HIFU revenue and a 167% growth in Focal One system placements, underscoring the growing demand for non-invasive prostate cancer treatments. Additionally, EDAP TMS S.A. secured a €36 million credit facility from the European Investment Bank to support further expansion and development of new clinical indications. Despite the positive growth in its core HIFU business, the company experienced a decline in its non-core ESWL and Distribution business revenues, reflecting a strategic shift towards focusing on high-growth opportunities in focal therapy. Looking ahead, EDAP TMS S.A. remains optimistic about its growth prospects, with management reiterating its financial guidance for 2025, expecting continued revenue growth in its HIFU business.